Skip to main content
Springer logoLink to Springer
. 2016 Sep 30;26(2):143–154. doi: 10.1007/s00787-016-0908-4

Can psychiatric childhood disorders be due to inborn errors of metabolism?

A Simons 1,2,4,, F Eyskens 1, I Glazemakers 2,4,5, D van West 2,3,4,5
PMCID: PMC5306168  PMID: 27695954

Abstract

Many patients who visit a centre for hereditary metabolic diseases remarkably also suffer from a child psychiatric disorder. Those child psychiatric disorders may be the first sign or manifestation of an underlying metabolic disorder. Lack of knowledge of metabolic disorders in child psychiatry may lead to diagnoses being missed. Patients therefore are also at risk for not accessing efficacious treatment and proper counselling. To search the literature for the co-occurrence of child psychiatric disorders, such as ADHD, autism, psychosis, learning disorders and eating disorders and metabolic disorders. A search of the literature was conducted by performing a broad search on PubMed, using the terms “ADHD and metabolic disorders”, “autism and metabolic disorders”, “psychosis and metabolic disorders”, “learning disorders and metabolic disorders”, and “eating disorders and metabolic disorders”. Based on inclusion criteria (concerning a clear psychiatric disorder and concerning a metabolic disorder) 4441 titles and 249 abstracts were screened and resulted in 71 relevant articles. This thorough literature search provides child and adolescent psychiatrists with an overview of metabolic disorders associated with child psychiatric symptoms, their main characteristics and recommendations for further investigations.

Keywords: Metabolic disorders, Child psychiatric disorder, ASD, ADHD, Learning disorder, Psychosis, Eating disorder

Introduction

Although a lot of research has already been done about organic causes of child psychiatric disorders, few of them focus on metabolic disorders as a possible cause of a child psychiatric disorder. Many children who visit our centre for hereditary metabolic diseases suffer from a child psychiatric disorder [1]. Metabolic disorders cover a variety of diseases in which there is an accumulation of toxic and/or complex compounds or energy problems within the cells due to enzymatic defects or other protein dysfunction (e.g., transporter defects).

Sometimes the psychiatric symptoms occur before irreversible neurological lesions. A number of metabolic disorders give rise to a major psychiatric disorder. These metabolic disorders can result in neuropsychiatric illness either through disruption of late neurodevelopmental processes, or via chronic or acute disruption of excitatory/inhibitory or monoaminergic neurotransmitter systems. This disruption to metabolic processes can lead to gross neurodevelopmental disruption with seizures and coma, or to mild disruption with intermittent and/or subtle cognitive, behavioural disturbance and psychiatric illness, such as psychosis [2]. To prevent or decrease mortality, morbidity and disabilities associated with metabolic diseases as much as possible, it is important to detect the metabolic disease as early as possible. For this reason, it is important that child and adolescent psychiatrists are aware of possible underlying metabolic disease in child psychiatric problems. This is of great importance because specific treatment may be available to prevent metabolic decompensation and further progression of disease can be avoided. In addition, many of these conditions have important implications for genetic counselling. This article gives an overview of the literature on co-occurring metabolic disorders and child psychiatry disorders and attempts to give child psychiatrists some recommendations on when to screen for metabolic disorders.

Method

We searched PubMed for articles published between 1 January 1980 and 31 December 2013, using the search terms: “ADHD and metabolic disorders”, “autism and metabolic disorders”, “psychosis and metabolic disorders”, “learning disorders and metabolic disorders”, and “eating disorders and metabolic disorders”. Concerning psychosis, we included articles about visual auditory or visual hallucinations, paranoid delusions, interpretative thoughts and schizophrenia. Articles were selected according the following criteria: (1) articles were written in English, (2) the article concerned a clear psychiatric disorder according the DSM-criteria and concerned a metabolic disorder, and (3) the article was not about a metabolic syndrome.

Our search resulted in 4441 initial hits, after screening titles and abstracts for inclusion and exclusion criteria, we studied the remaining 249 articles and concluded that only 71 were actually relevant (and not concerning the metabolic syndrome). Figure 1 shows the flow diagram that was used for all psychiatric disorders in the literature search; Table 1 specifies the search results for each psychiatric disorder separately.

Fig. 1.

Fig. 1

Flow diagram showing process of literature search

Table 1.

Results of PubMed search by type of psychiatric disorder

Type of psychiatric disorder Number of titles found Number of abstracts viewed Numbers of articles included for review
ADHD 316 34 10
Autism 559 101 19
Eating disorders 1513 18 5
Learning disorders 726 49 17
Psychosis 1327 47 20
Total (including review) 4441 249 71

Psychiatric disorders such a depression and anxiety disorders were not included in the search because based on clinical experience and earlier research [1], we expect these disorders rather to be a consequence of dealing with the diagnosis of and life with a metabolic disease than that they share a common underlying disruption.

Literature search

There is a lack of review articles on the subject. Only three reviews on psychiatric symptoms and metabolic disorders were found.

One by Sedel et al. [3] proposed a classification of metabolic diseases into three groups according to the type of psychiatric signs at onset. Group 1 represents psychiatric emergencies, namely acute and recurrent attacks of confusion and behavioural changes, sometimes misdiagnosed as acute psychosis. This includes urea cycle defects, homocysteine remethylation defects and porphyrias. Group 2 includes diseases with chronic psychiatric symptoms arising in adolescence or adulthood. These psychiatric symptoms can be recurrent psychotic attacks, chronic delusion or disorganized behaviour, and behavioural and personality changes. Among these diseases are homocystinurias, Wilson disease, adrenoleukodystrophy and some lysosomal storage disorders. Group 3 is characterized by mild mental retardation and late-onset behavioural or personality changes. This group includes homocystinurias, cerebrotendinous xanthomatosis, nonketotic hyperglycinemia, monoamine oxidase A deficiency, succinic semialdehyde dehydrogenase deficiency, creatine transporter defect, and alpha-/beta-mannosidosis. In this paper, a diagnostic strategy to guide metabolic investigations in a patient with atypical psychiatric signs is proposed.

Another article by Estrov et al. [4] reviewed four metabolic diseases: phenylketonuria (PKU), Wilson disease, acute intermittent porphyria (AIP) and metachromatic leukodystrophy (MLD). Early treated PKU can exhibit depressed mood, anxiety (esp agoraphobia) and psychosocial difficulties. Wilson disease can present with personality changes, depressive episodes, cognitive dysfunction and psychosis. AIP is often associated with symptoms of anxiety, depression, psychosis and altered mental status as psychiatric manifestations. MLD frequently presents with psychosis followed by intellectual deterioration.

In 2013, Walterfang et al. [2] wrote a review on the neuropsychiatry of inborn errors of metabolism. In this article, following metabolic disorders are also associated with psychiatric symptoms: metachromatic leukodystrophy, GM2 gangliosidosis, adrenoleukodystrophy, Niemann–Pick type C disease, cerebrotendinous xanthomatosis, neuronal ceroid lipofuscinosis, alpha-mannosidosis, Fabry disease, AIP, maple syrup urine disease, urea cycle disorders, disorders of homocysteine metabolism and PKU. Remarkably, there is an increase in reports the latest years about mitochondrial dysfunctioning and several neurodevelopment disorders, such as ASD, learning disorders, ADHD, schizophrenia and mood disorders [5, 6]. A mitochondrial dysfunction leads to an energy problem and neural synapses are areas of high energy consumption.

Autism spectrum disorders

About the link of autism spectrum disorder (ASD) and metabolic disorders four review articles were found [79]. In these four reviews, concerning ASD and metabolic disorders, similar findings are reported. Known metabolic disorders in autism are phenylketonuria, disorders in purine metabolism (such as adenosine deaminase deficiency, adenylosuccinate lyase deficiency, dihydropyrimidine dehydrogenase and dihydropyrimidinase deficiencies), organic acidurias (such as propionic academia, 3-methylcrotonyl-CoA carboxylase deficiency and pyridoxine dependency), disorders of branched-chain amino acids creatine deficiency, biotinidase deficiency, cerebral folate deficiency, succinic semialdehyde dehydrogenase deficiency, Smith–Lemli–Opitz syndrome (SLOS), late infantile ceroid lipofuscinosis, histidinemia, Sanfilippo disease, glucose 6-phosphate dehydrogenase deficiency, urea cycle disorders, X-linked ichthyosis, and mitochondrial disorders. In most of these disorders, there is also mental or psychomotor retardation.

In addition, case reports and some small studies about these diseases were found [1014]. Benvenuto [15] names PKU, adenylosuccinase deficit, SLOS, creatine deficiency syndromes and mitochondrial disorders as possible causes of syndromic autism. Case reports of autism in association with acute intermittent porphyria [16], propionic academia [17] and L-2-hydroxyglutaric aciduria [18] were found. Kaluzna-Czaplinska [19] focusses on the role of homocysteine in autism. A high level of blood and urinary homocysteine is associated with pathophysiology of ASD and may serve as a diagnostic tool for the detection of nutrient deficiencies (folate, vitamin B12) in autistic children. The last years several studies were done suggesting a disturbance of mitochondrial energy production as an underlying pathophysiological mechanism in autism [2022]. Frye [6] states that children with ASD and a mitochondrial disorder appear to have a higher prevalence of medical disorders such as gastrointestinal problems, seizures and gross motor delay. An interesting study was done in Greece [23] where they screened 187 children with confirmed features of ASD for the presence of inborn errors of metabolism. Their data provide evidence for a new biomarker (3-OH-IVA) and novel treatment approaches in ASD patient. Biotin supplementation or institution of a ketogenic diet resulted in mild to significant clinical improvement in the autistic features. Table 2 summarizes, based on the literature, when ASD is combined with specific other psychiatric, neurodevelopmental or somatic problems with metabolic diseases can be an underlying cause.

Table 2.

Possible underlying metabolic diseases in ASD

Associated signs and symptoms Possible underlying metabolic disease Other signs and symptoms of the metabolic disease Onset of the metabolic disease
Mental retardation and behavioural problems (such as aggressive behaviour, hyperactivity, impulsivity, agitation) Untreated PKU
Disorders in purines metabolism
Lesh–Nyhan
Succinic semialdehyde dehydrogenase deficiency
Smith–Lemli–Opitz syndrome
Mucopolysaccharidosis type II (Hunter)
X-linked ichthyosis
Seizures, eczema
Seizures, spastic paraplegia, self-mutilation
Seizures, hypotonia, ataxia, intermittent lethargy, speech delay
Feeding difficulties in infancy, muscle hypotonia, facial dysmorphism, expressive language disorders, excessive screaming in early childhood, genital abnormalities in the male
Retinitis pigmentosa, chronic diarrhoea, regression, sleep problems
Scaly skin on the scalp, trunk and limbs (ichthyosis)
Neonatal
First years
After 3 months
After infancy
During first year
From birth
Regression Cerebral folate deficiency
Mucopolysaccharidosis type II (Hunter)
Deceleration of head growth, psychomotor retardation, cerebellar ataxia, dyskinesias, seizures, apnea, megaloblastic anaemia
Cfr supra
1 -12 months
Cfr supra
Seizures or epilepsy Untreated PKU
Disorders in purines metabolism
Dihydropyrimidine dehydrogenase deficiency
Dihydropyrimidinase
Deficiency
Cerebral Creatine deficiency
Biotinidase deficiency
Biotinidase or Late-onset carboxylase deficiency
Succinic semialdehyde dehydrogenase deficiency
Late infantile ceroid lipofuscinosis
Urea cycle disorders
Hyperammonaemia
Acute intermittent porphyria (AIP)
L-2-hydroxyglutaric aciduria
Mitochondrial disorders
OXPHOS defects
Cfr supra
Cfr supra
Psychomotor retardation, growth retardation, failure to thrive, microcephaly, ocular abnormalities, self-mutilation, muscle weakness, haemolytic anaemia, asymptomatic patients
Extrapyramidal signs, speech delay
Ataxia, hypotonia,
organic acidemia, alopecia, skin rash, visual and hearing loss
Cfr supra
Developmental delay, speech acquisition delay, myoclonus, ataxia, choreiform movement, visual loss, dementia
Hepatomegaly, abnormal hair, hepatic fibrosis, intellectual and developmental disabilities, learning disabilities, confusion, delusion, tone change, reflex abnormalities, vomiting, headache, changing food habits
Anxiety, restlessness, insomnia, psychosis, aggressive and impulsive behaviour, catatonia, intestinal problems, dark urine, skin lesions, acute peripheral neuropathy (paralysis of diaphragm) acroparesthesia
Developmental retardation, macrocephaly, cerebellar ataxia
Central nervous system dysfunction, behavioural disturbance, cognitive impairment, motor disturbances, muscle hypotonia and exercise intolerance
Cfr supra
Cfr supra
During first year
3 months –2 year
1–12 months
Cfr supra
After 2 years
From birth
OTC is a X-linked disorder with episodic clinical presentation in females
Adolescence to adulthood
Especially in women
Childhood
From infancy to adulthood
Speech or language impairment Cerebral Creatine deficiency
Smith–Lemli–Opitz syndrome
Late infantile ceroid lipofuscinosis
Histidinemia
Propionic acidemia
Cfr supra
Cfr supra
Cfr supra
Mental retardation, asymptomatic patients
Behavioural problems, hyperammonaemia, metabolic acidosis
Cfr supra
Cfr supra
Cfr supra
Infancy to childhood
Neonatal and infancy

Attention deficit hyperactivity disorder

The literature search found several studies concerning the prevalence of attention deficit hyperactivity disorder (ADHD) in persons with a metabolic disorder. Knerr [11] studied a population of 33 subjects with succinic semialdehyde dehydrogenase deficiency of which 28 % showed behavioural problems such as attention deficit and hyperactivity. In addition, autistic features were found in these patients. The patients in this population also have psychomotor retardation. In a population of 25 boys with X-linked ichthyosis [14], 40 % fulfilled DSM-IV criteria for a diagnosis of ADHD. ADHD in children with PKU is well documented in several papers. Antshel [24, 25] stated that prenatal exposure to elevated levels of phenylalanine is associated with a higher likelihood of expressing hyperactive/impulsive symptoms and postnatal exposure is associated with a higher likelihood of expressing inattentive symptoms. Arnold [26] performed a study in 38 children with PKU and found that 26 % of this children use stimulant medication for attentional dysfunction, which is significantly higher than in an age- and sex-matched control group. Case reports of ADHD in a child with a metabolic disorder were found for 3-methylcrotonyl-CoA carboxylase deficiency [27], argininosuccinate lyase deficiency [28] and succinyl-CoA: 3-oxoacid CoA transferase deficiency [29].

Wijburg et al. [30] stated that mucopolysaccharidosis III (Sanfilippo disease), which is characterized by progressive cognitive decline and severe hyperactivity, is often misdiagnosed as an idiopathic developmental delay, ADHD or ASS. ADHD is also linked to mitochondrial disorders [5]. An overview of the metabolic disorders associated with ADHD is summarized in Table 3.

Table 3.

Possible underlying metabolic diseases in ADHD

Associated symptoms and signs Possible underlying metabolic disease Other symptoms and signs of the metabolic disease Onset of the metabolic disease
Autism and mental retardation Untreated PKU
Succinic semialdehyde dehydrogenase deficiency
X-linked ichthyosis
Mitochondrial disorders
Mental retardation, seizures
Hypotonia, speech delay, seizures, ataxia, psychomotor retardation, intermittent lethargy
Scaly skin on the scalp, trunk and limbs (ichthyosis), mental retardation
Central nervous system dysfunction, behavioural disturbance, cognitive impairment, motor disturbances, seizures, muscle hypotonia and exercise intolerance
Neonatal
After 3 months
From birth
From infancy to adulthood
Speech delay Succinic semialdehyde dehydrogenase deficiency
Succinyl-CoA: 3 oxo acid CoA transferase (SCOT) deficiency
Mucopolysaccharidosis
Type III (Sanfilippo syndrome)
Cfr supra
Ketoacidotic crises, persistent ketosis, lethargy, coma, speech and behavioural problems, sleep disorders, anxiety, hallucinations, aggressive behaviour, seizures
Developmental or speech delay after a period of normal development, behaviour problems, hyperactivity, mild facial dysmorphism, frequent ear and respiratory infections, chronic diarrhoea
Cfr supra
Infancy to adulthood
Childhood
Hypotonia Succinic semialdehyde dehydrogenase deficiency
Nonketotic hyperglycaemia
3-methylcrotonyl-CoA carboxylase deficiency
Cfr supra
History of infantile hypotonia and feeding difficulties, mental retardation, ADHD, outburst of aggressiveness, sexual impulsivity
Neurological abnormalities and death in infancy, feeding difficulties, recurrent episodes of vomiting and diarrhoea, lethargy, secondary carnitine deficiency, asymptomatic patients
Cfr supra
Infancy to adulthood
Infancy to adulthood

Learning disorders

Taking learning disorders into consideration, some reports are found showing a link between learning disorders and adrenoleukodystrophy [31, 32] and MLD [33], which is associated with nonverbal learning disability. Gordon [34] reported about glucose transporter type 1 deficiency as a preventable cause of severe learning difficulties. Children with PKU show lower IQ, slow information processing, reduced learning capacity, mild executive impairments, and educational difficulties [35]. Antshel [24, 25] also reports in a review that young adults with PKU are more likely to have academic difficulties than their non-PKU peers, especially in maths. This is due to ADHD but also to executive functioning deficits and processing speed deficits. Janzen [36] stated that individuals with PKU also have nonexecutive cognitive abilities, such as problems with information speed processing, fine motor control, and perception and visual-spatial abilities. In an American longitudinal observation with 108 individuals with urea cycle disorders, 35 % had learning disabilities [37]. Lichter [38] specified this for OTC-deficiency. Special emphasis in this article was made on the late-onset (partial) disease, who can present from infancy to adulthood. A hyperammonemic crisis can lead to a life-threatening event and neuropsychological complications, such as developmental delay, ADHD and executive function deficits. Potter [39] studied 43 children with galactosemia and a history of speech sound disorders. 56 % of the children with typical cognitive development and 88 % of the children with borderline-low cognitive development showed language impairments. The first group had more often an expressive language disorder, the second group more often a mixed receptive-expressive language disorder. Bahi-Buisson [40] examined 22 patients with hyperinsulinism-hyperammonaemia syndrome and found a learning disability in 17 patients. Case reports were found about the occurrence of learning disorders in glutaric aciduria type I [41] and generalised uridine diphosphate galactose-4-epimerase deficiency [42]. Learning difficulties are also reported in Niemann-Pick disease type C [43]. Patients with juvenile neuronal ceroid lipofuscinosis show learning delay and regression of acquired skills [44]. Brady [45] described two cases with mucopolysaccharidosis type IIIB presenting as children with behavioural issues and mild learning disabilities, and having a rapid cognitive decline in early adulthood (see Table 4 for an overview).

Table 4.

Possible underlying metabolic disease in learning disorders

Associated signs and symptoms Possible underlying metabolic disease Other symptoms and signs of the metabolic disease Onset of the metabolic disease
Neurodegeneration Adrenoleukodystrophy
(X-linked)
Metachromatic leukodystrophy
Glutaric aciduria type 1
Mucopolysaccharidosis
Type III (Sanfilippo syndrome)
Variable phenotype, deterioration in school performance, dementia, vision loss, sensorineural hearing loss, brain white matter abnormalities on MRI, adrenal insufficiency
Progressive neurodegeneration. Nonverbal learning disability syndrome, spasticity, brain white matter abnormalities, peripheral neuropathy
Acute regression after an initial phase of (almost) normal development (acute encephalopathic crisis), severe dystonic-dyskinetic movement disorder, macrocephaly, MRI of the brain: fronto-temporal atrophy
Developmental or speech delay after a period of normal development, behaviour problems, hyperactivity, mild facial dimorphism, frequent ear and respiratory infections, chronic diarrhoea
Childhood to adulthood
Infancy to adulthood
6 months to 2 years
Childhood
Seizures Untreated PKU
Glucose transporter type 1 deficiency
Hyperinsulinism-Hyperammonaemia syndrome
Urea cycle disorders
Juvenile neuronal ceroid lipofuscinosis
Autism, ADHD, mental retardation, executive impairment
Delayed development in infancy with acquired microcephaly (cerebral/cerebellar atrophy), ataxia
Hypoglycaemia, weakness, shakiness, rapid pulse, confusion
Hepatomegaly, abnormal hair, hepatic fibrosis, intellectual and developmental disabilities, learning disabilities, tone change, reflex abnormalities, vomiting
Progressive deterioration of cognition, ataxia, spasticity, vision loss, learning delay, regression of acquired skills
Neonatal
Neonatal
Infancy
From birth on
Infancy to adulthood
Vomiting and/or diarrhoea Galactosemia
Urea cycle disorders
Mucopolysaccharidosis
Type III (Sanfilippo syndrome)
Lethargy, vomiting, diarrhoea, failure to thrive, jaundice, cataract, speech difficulties, learning disorders, tremor, ovarian failure, osteoporosis
Cfr supra
Cfr supra
Infancy to childhood
Cfr supra
Cfr supra

Psychosis

Psychosis, what can be auditory or visual hallucinations, paranoid delusions, and interpretative thoughts, and can be a symptom of schizophrenia, is described in alpha-mannosidosis [46, 47] and also in other lysosomal storage diseases: late-onset Tay–Sachs disease [48] and Fabry disease [49, 50]. Psychosis is also seen in mitochondrial disorders, in particular, respiratory chain defects [5, 51, 52]. Wilson’s disease can present with psychosis, but also as personality and mood changes, depression, phobias, cognitive impairment, anxiety and compulsive and impulsive behaviour [5355]. A clinical presentation of metachromatic leukodystrophy during adolescence and/or adulthood may be psychosis [56]. If a post pubertal patient presents with acute mental changes and hallucinations or psychosis, acute porphyria should be considered [57]. In addition, a link between a disturbed homocysteine metabolism and schizophrenia is described [58]. Psychosis is also described in Niemann-Pick type C [59, 60]. Also, behavioural disturbances occur in this disease (see Table 5 for an overview).

Table 5.

Possible underlying metabolic diseases in psychosis

Associated signs and symptoms Possible underlying metabolic disease Other symptoms and signs of the metabolic disease Onset of the metabolic disease
Seizures Mitochondrial disorders
Acute intermittent porphyria (AIP)
Urea cycle disorders
Methylenetetrahydrofolate reductase deficiency
Central nervous system dysfunction, behavioural disturbance, cognitive impairment, motor disturbances, autism
Anxiety, restlessness, insomnia, neuropathy, psychosis, aggressive and impulsive behaviour, catatonia, intestinal problems, dark urine, skin lesions, epilepsy, acute peripheral neuropathy
Hepatomegaly, abnormal hair, hepatic fibrosis, intellectual and developmental disabilities, learning disabilities, confusion, delusion, seizure disorders, muscle tone change, reflex abnormalities, vomiting, changing food habits, headache
Mild or severe depending on the enzyme activity: encephalopathy, gait disturbance, paraparesis, arterial or venous thrombosis and strokes, neurocognitive impairment, feeding problems, spasticity
Infancy to adulthood
Adolescence and adulthood
Infancy to adulthood
Infancy to adulthood
Mental retardation Alpha-
Beta-mannosidosis
Niemann–Pick type C
Homocystinuria
Immune deficiency, facial and skeletal abnormalities, hearing impairment, intellectual disability, progressive neurological signs, episodes of confusion and psychosis followed by a period of confusion, somnolence and asthenia
Hepatosplenomegaly, cerebellar ataxia, dysarthria, vertical gaze palsy, cognitive difficulties, progressive neurological deterioration, psychotic symptoms, schizophrenia, behavioural disturbances (aggressiveness, self-mutilation, social isolation, laughing), depressive episodes, bipolar disorders, obsessive–compulsive disorders, infantile cholestatic icterus
Lens dislocation, Marfan-like appearance, thromboembolic events, schizophrenia or psychotic episodes (rare), behavioural disorders, depression, obsessive–compulsive disorder, disorganized behaviour, delusions, depression, alteration of consciousness, peripheral neuropathy, coma, paraplegia, strokes, thromboembolic events
Infancy
From childhood to adolescence
Infancy to adulthood
Depression Wilson’s disease
Fabry’s disease
(X-linked)
Tay–Sachs/
Sandhoff disease or GM2 gangliosidosis
Niemann–Pick type C Homocystinuria
Ophtalmology: Kayser-Fleisher rings mood disorders, behavioural and personality disorders, cognitive impairment, psychotic symptoms, dysarthria, anxiety
Neural pain in hands and feet, cornea verticillata, hearing loss, stroke, renal dysfunction, proteinuria, asymmetric cardiac hypertrophy, angiokeratoma
Speech and swallowing difficulties, unsteadiness of gait, spasticity, dystonia, cognitive decline, schizophrenia like psychosis, depression, mania, lower motor neuron disease, sensitive polyneuropathy, dysautonomia, spastic fright reaction, ophthalmology: cherry red spot, blindness
Cfr supra
Cfr supra
Adolescence and adulthood
Adolescence and adulthood
Infancy to adulthood
Cfr supra
Cfr supra

Eating disorders

Concerning eating disorders and metabolic disorders only five relevant articles were found. Touati [61] describes frequent feeding disorders in children with methylmalonic and propionic acidurias, in which up to 60 % of patients needed a food supplement by tube. Deutsch et al. [62] report about a woman with anorexia nervosa and a mitochondrial myopathy, suggesting the possibility that the eating disorder was causally related to a more fundamental defect in mitochondrial oxidative metabolism. Symptoms of anorexia nervosa were also described in MELAS [63] and mitochondrial encephalomyopathy [64]. Sedel [3] mentions in his review that patients with a urea cycle disorder often experience protein intolerance and change their food habits becoming vegetarian or anorexic. Also, Gardeitchik [65] reports that protein aversion can be a diagnostic clue in patients presenting with food refusal, recurrent vomiting, behavioural problems, mental retardation and episodes of altered consciousness (see Table 6 for an overview).

Table 6.

Possible underlying metabolic diseases in eating disorders

Possible underlying metabolic disease Other symptoms and signs of the metabolic disease Onset of the metabolic disease
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) Severe cachexia, gastrointestinal dysmotility, progressive external ophthalmoplegia, peripheral neuropathy Infancy to adulthood
Mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS) Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes Infancy to adulthood
Methylmalonic and propionic aciduria Developmental delay, cardiomyopathy, renal failure, opticus atrophy From birth
Urea cycle disorders Hepatomegaly, abnormal hair, hepatic fibrosis, intellectual and developmental disabilities, learning disabilities, confusion, delusion, seizure disorders, muscle tone change, reflex abnormalities, vomiting, headache, changing food habits Infancy to adulthood

Conclusions

The literature search concerning metabolic disorders and child psychiatric disorders was performed. Metabolic diseases represent rare but important causes of psychiatric diseases that remain isolated for years before more specific organic signs become obvious [3]. Psychiatrist should be aware of inborn errors of metabolism. In the literature, most relevant articles were found concerning ASD and psychosis in combination with a metabolic disorder. Based on the literature an overview for the different psychiatric disorders in the scoop of this paper was made in the combination with others signs and symptoms. This overview gives the child and adolescent psychiatrist some direction for further investigations and referral to a metabolic unit.

In the literature search, no guidelines were found when to look for a metabolic disease in a child presenting with a psychiatric disorder. A broad metabolic screening or routine metabolic screening carriers a low yield [8]. A metabolic work-up must be reserved for patients with clinical indicators of a metabolic disorder [8, 15, 66].

Further investigations are warranted in case of [3, 8, 15]:

  • A positive family history of metabolic disease.

  • Symptoms or signs are triggered by food intake (esp high protein content foods), fever, fasting, surgery (catabolism).

  • Feeding difficulties, food refusal, failure to thrive, eating disorders combined with symptoms of myopathy or fatigue.

  • Mental retardation and/or regression.

  • Epilepsy, episodes of lethargy or confusion.

  • Dysmorphic feature.

In most cases, there is a combination of neurological signs (epilepsy, ataxia, and catatonia), cognitive and motor dysfunction (hypotonia, hypertonia) and systemic signs of diverse organic involvement, cardiomyopathy, liver dysfunction, renal problems, immune deficiency, anaemia, and gastrointestinal problems (diarrhoea, obstipation, and pseudo-obstruction).

In this review, we did not include depression and anxiety disorders. The reason for this is that the focus of this review is on metabolic disorders as a comorbidity sharing similar pathogenesis, and a child psychiatric disorder being a clue to think about a metabolic disorder. In clinical practice, we see depression and anxiety after the diagnosis of a metabolic disorder, but rarely as a predictor of a metabolic disorder [1, 4]. Nevertheless, in the process of the literature search, we found a few metabolic diseases presenting with depressive episodes or anxiety such as Wilson disease and AIP [4] (see also Table 5).

This review is written from the perspective of a child and adolescent psychiatrist. The literature shows us that psychiatric diseases in adulthood can also reveal a metabolic disorder [3]. For instance, postpartum psychosis can be caused by a urea cycle disorder [6769] and by GM2 gangliosidosis [70] and psychosis is also described in methylenetetrahydrofolate reductase deficiency (MTHFR) [71]. Therefore, knowledge of metabolic disease and their psychiatric manifestations is also warranted for adult psychiatrists. Finally, we hope to encourage the inclusion of inborn errors of metabolism in the differential diagnosis of psychiatric disease when appropriate as to allow and facilitate a prompt and correct diagnosis, followed by an effective treatment.

Abbreviations

OXPHOS

Oxidative phosphorylation

OTCD

Ornithine transcarbamylase deficiency

3-OH-IVA

3-hydroxyisovaleric acid

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Contributor Information

A. Simons, Email: annik.simons@zna.be, Email: anniksimons@hotmail.com

F. Eyskens, Email: francois.eyskens@uza.be

I. Glazemakers, Email: inge.glazemakers@uantwerpen.be

D. van West, Email: dirk.vanwest@zna.be

References

  • 1.Simons A, Eyskens F, De Groof A, Van Diest E, Deboutte D, Vermeiren R. Cognitive functioning and psychiatric disorders in children with a metabolic disease. Eur Child Adolesc Psychiatry. 2006;15:207–213. doi: 10.1007/s00787-006-0524-9. [DOI] [PubMed] [Google Scholar]
  • 2.Walterfang M, Bonnot O, Mocellin R, Velakoulis D. The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis. 2013;36:687–702. doi: 10.1007/s10545-013-9618-y. [DOI] [PubMed] [Google Scholar]
  • 3.Sedel F, Baumann N, Turpin J, Lyon-Caen O, Saudubray J, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metabol Dis. 2007;30:631–641. doi: 10.1007/s10545-007-0661-4. [DOI] [PubMed] [Google Scholar]
  • 4.Estrov Y, Scaglia F, Bodamer OA. Psychiatric symptoms of inherited metabolic disease. J Inherit Metabol Dis. 2000;23:2–6. doi: 10.1023/A:1005685010766. [DOI] [PubMed] [Google Scholar]
  • 5.Marazziti D, Baroni S, Pichetti M, Landi P, Silvestri S, Vatteroni E, et al. Psychiatric disorders and mitochondrial dysfunctions. Eur rev Med Pharmacol Sci. 2012;16:270–275. [PubMed] [Google Scholar]
  • 6.Frye R, Rossignol D. Mitochondrial and metabolic abnormalities in neurodevelopmental disorders. J of Ped Biochem. 2012;2:177–180. [Google Scholar]
  • 7.Ghaziuddin M, Al-Owain M. Autism spectrum disorders and inborn errors of metabolism: an update. Pediatr Neurol. 2013;49:232–236. doi: 10.1016/j.pediatrneurol.2013.05.013. [DOI] [PubMed] [Google Scholar]
  • 8.Zecavati N, Spence S. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep. 2009;9:129–136. doi: 10.1007/s11910-009-0021-x. [DOI] [PubMed] [Google Scholar]
  • 9.Manzi B, Loizzo A, Giana G. Curatolo. Autism and metabolic diseases. J Child Neurol. 2008;23:307–314. doi: 10.1177/0883073807308698. [DOI] [PubMed] [Google Scholar]
  • 10.Knerr I, Gibson K, Jakobs C, Pearl P. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr. 2008;13:598–605. doi: 10.1017/S1092852900016874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Jurecka A, Zikanova M, Tylki-Szymanska A, Krijt J, Bogdanska A, Gradowska W, et al. Clinical, biochemical and molecular findings in seven Polish patients with adenylosuccinate lyase deficiency. Mol Genet Metab. 2008;94:435–442. doi: 10.1016/j.ymgme.2008.04.013. [DOI] [PubMed] [Google Scholar]
  • 12.Gorker I, Tuzun U. Autistic-like findings associated with a urea cycle disorder in a 4-year-old girl. J Psychiatry Neurosci. 2005;30:133–135. [PMC free article] [PubMed] [Google Scholar]
  • 13.Kent L, Emerton L, Bhadravathi V, Weisblatt E, Pasco G, Willatt L, et al. X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet. 2008;45:519–524. doi: 10.1136/jmg.2008.057729. [DOI] [PubMed] [Google Scholar]
  • 14.Zaffanello M, Zamboni G, Fontana E, Zoccante L, Tato L. A case of partial biotinidase deficiency associated with autism. Child Neuropsychol. 2003;9:184–188. doi: 10.1076/chin.9.3.184.16457. [DOI] [PubMed] [Google Scholar]
  • 15.Benvenuto A, Moavero R, Alessandrelli R, Manzi B, Curatolo P. Syndromic autism: causes and pathogenetic pathways. World J Pediatr. 2009;5:169–176. doi: 10.1007/s12519-009-0033-2. [DOI] [PubMed] [Google Scholar]
  • 16.Luder A, Mamet R, Farbstein I, Schoenfeld N. Awareness is the name of the game: clinical and biochemical evaluation of a case diagnosed with acute intermittent porphyria associated with autism. Cell Mol Biol. 2009;55:19–22. [PubMed] [Google Scholar]
  • 17.Al-Owain M, Kaya N, Al-Shamrani H, Al-Bakheet A, Qari A, Al-Muaigl S, Ghaziuddin M. Autism spectrum disorder in a child with propionic academia. JIMD rep. 2013;7:63–66. doi: 10.1007/8904_2012_143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zafeiriou D, Ververi A, Salomons G, Vargiami E, Haas D, Papadopoulou V, et al. L-2-Hydroxyglutaric aciduria presenting with severe autistic features. Brain Dev. 2008;30:305–307. doi: 10.1016/j.braindev.2007.09.005. [DOI] [PubMed] [Google Scholar]
  • 19.Kaluzna-Czaplinska J, Zurawicz E, Michalska M, Rynkowski J. A focus on homocysteine in autism. Acta Biochim Pol. 2013;60:137–142. [PubMed] [Google Scholar]
  • 20.Weissman J, Kelley R, Bauman M, Cohen B, Murray K, Mitchell R, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One. 2008;3:e3815. doi: 10.1371/journal.pone.0003815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Oliveira G, Diogo L, Grazina M, Garcia P, Ataide A, Marques C, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol. 2005;47:185–189. doi: 10.1017/S0012162205000332. [DOI] [PubMed] [Google Scholar]
  • 22.Poling J, Frye R, Shoffner J, Zimmerman A. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol. 2006;21:170–172. doi: 10.1177/08830738060210021401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Spilioti M, Evangeliou A, Tramma D, Theodoridou Z, Metaxas S, Michailidi E, et al. Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD) Front Hum Neurosc. 2013;7:858. doi: 10.3389/fnhum.2013.00858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Antshel K. ADHD, learning, and academic performance in phenylketonuria. Mol Gen Met. 2010;99:S52–S58. doi: 10.1016/j.ymgme.2009.09.013. [DOI] [PubMed] [Google Scholar]
  • 25.Antshel K, Waisbren S. Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol. 2003;31:565–574. doi: 10.1023/A:1026239921561. [DOI] [PubMed] [Google Scholar]
  • 26.Arnold G, Vladutiu C, Orlowski C, Blakely E, Deluca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis. 2004;27:137–143. doi: 10.1023/B:BOLI.0000028725.37345.62. [DOI] [PubMed] [Google Scholar]
  • 27.Darin N, Andersen O, Wiklund L, Holmgren D, Holme E. 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis. Pediatr Neurol. 2007;36:132–134. doi: 10.1016/j.pediatrneurol.2006.09.007. [DOI] [PubMed] [Google Scholar]
  • 28.Nagamani S, Erez A, Lee B (2011) Argininosuccinate lyase deficiency. In: Pagon R, Adam M, Bird T, Dolan C, Fong C, Smith R, Stephens K (eds) GeneReviews. Seattle (WA), University of Washington, Seattle, 1993–2013 [PubMed]
  • 29.Berry G, Fukao T, Mitchell G, Mazur A, Ciafre M, Gibson J, et al. Neonatal hypoglycaemia in severe succinyl-CoA: 3-oxoacid CoA-transferase deficiency. J Inherit Metabol Dis. 2001;2001(24):587–595. doi: 10.1023/A:1012419911789. [DOI] [PubMed] [Google Scholar]
  • 30.Wijburg F, Wegrzyn G, Burton B, Tylki-Szymanska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Pediatrica. 2013;102:462–470. doi: 10.1111/apa.12169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bakos J, Goen P, Ogden A, Brown F. Karaviti. Adrenoleukodystrophy: a link between adrenal insufficiency and school performance. J Clin Endocrinol Metab. 1995;80:2869–2872. doi: 10.1210/jcem.80.10.7559867. [DOI] [PubMed] [Google Scholar]
  • 32.Kotagal S, Geller T, Wall D, Lastra C. A child with reading impairment and a family history of adrenoleukodystrophy. Semin Pediatr Neurol. 1999;6:233–236. doi: 10.1016/S1071-9091(99)80020-5. [DOI] [PubMed] [Google Scholar]
  • 33.Weber Byars A, Mcellop J, Gyato K, Sullivan T, Franz D. Metachromatic leukodystrophy and nonverbal learning disability: neuropsychological and neuroradiological findings in heterozygous carriers. Child Neuropsychol. 2001;7:54–58. doi: 10.1076/chin.7.1.54.3146. [DOI] [PubMed] [Google Scholar]
  • 34.Gordon N, Newton R. Glucose transporter type1 (GLUT-1) deficiency. Brain Dev. 2000;25:477–480. doi: 10.1016/S0387-7604(03)00058-5. [DOI] [PubMed] [Google Scholar]
  • 35.Anderson P, Wood S, Francis D, Coleman J, Anderson V, Boneh A. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels? Dev Neuropsychol. 2007;32:645–668. doi: 10.1080/87565640701375963. [DOI] [PubMed] [Google Scholar]
  • 36.Janzen D, Nguyen M. Beyond executive function: non-executive cognitive abilities in individuals with PKU. Mol Gen Met. 2010;99:S47–S51. doi: 10.1016/j.ymgme.2009.10.009. [DOI] [PubMed] [Google Scholar]
  • 37.Tuchman M, Lee B, Lichter-Konecki U, Summar M, Yudkoff M, Cederbaum S, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Gen Met Mol Gen Met. 2008;94:397–402. doi: 10.1016/j.ymgme.2008.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lichter-Konecki U, Caldovic L, Morizono H, Simpson K (2013). In: Pagon R, Adam M, Dolan C, Fong C, Stephens K (eds.) GeneReviews. Seattle(WA), University of Washington, Seattle, 1993–2013 [PubMed]
  • 39.Potter N, Lazarus J, Johnson J, Steiner R, Shriberg L. Correlates of language impairment in children with galactosaemia. J Inherit Metab Dis. 2008;31:524–532. doi: 10.1007/s10545-008-0877-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Bahi-Buisson N, Roze E, Dionisi C, Escande F, Valayannopoulos V, Feillet F, et al. Neurological aspects of hyperinsulinism-hyperammonaemia syndrome. Dev Med Child Neurol. 2008;50:945–949. doi: 10.1111/j.1469-8749.2008.03114.x. [DOI] [PubMed] [Google Scholar]
  • 41.Patil N, Shinde S, Karande S, Kulkarni M. Glutaric aciduria type I associated with learning disability. Indian J Pediatr. 2004;71:948. [PubMed] [Google Scholar]
  • 42.Walter J, Roberts R, Besley G, Wraith J, Cleary M, Holton J, et al. Generalised urindine diphosphate galactose-4-epimerase deficiency. Arch Dis Child. 1999;4:374–376. doi: 10.1136/adc.80.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sévin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier M, Sedel F. The adult form of Niemann-Pick disease type C. Brain. 2007;130:120–133. doi: 10.1093/brain/awl260. [DOI] [PubMed] [Google Scholar]
  • 44.Pérez-Poyato M, Milà Recansens M, Ferrer Abizanda I, Montero Sanchez R, Rodriguez-Revenga L, Cusi Sanchez V. Juvenile neuronal ceroid lipofuscinosis: clinical course and genetic studies in Spanish patients. J Inherit Metab Dis. 2012;34:1083–1093. doi: 10.1007/s10545-011-9323-7. [DOI] [PubMed] [Google Scholar]
  • 45.Brady J, trehan A, Landis D, Toro C (2013) Mucopolysaccharidosis type IIIB (MPS IIIB) masquerading as a behavioural disorder. BMJ Case Rep 8:2013 [DOI] [PMC free article] [PubMed]
  • 46.Gutschalk A, Harting I, Cantz M, Springer C, Rohrschneider K, Meinck H. Adult alpha-mannosidosis: clinical progression in the absence of demyelination. Neurology. 2004;63:1744–1746. doi: 10.1212/01.WNL.0000143057.25471.4F. [DOI] [PubMed] [Google Scholar]
  • 47.Malm D, Nilssen O. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21. doi: 10.1186/1750-1172-3-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Shapiro B, Logigian E, Kolodny E, Pastores G. Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients. Muscle Nerve. 2008;38:1012–1015. doi: 10.1002/mus.21061. [DOI] [PubMed] [Google Scholar]
  • 49.Staretz-Chacham O, Choi J, Wakabayashi K, Lopez G, Sidransky E. Psychiatric and behavioral manifestations of lysosomal storage disorders. Am J Med Genet B Neuropsychiatr Genet. 2010;5:1253–1265. doi: 10.1002/ajmg.b.31097. [DOI] [PubMed] [Google Scholar]
  • 50.Gairing S, Wiest R, Metzler S, Theodoridou A, Hoff P. Fabry’s disease and psychosis: causality or coincidence? Psychopathology. 2011;44:201–204. doi: 10.1159/000322794. [DOI] [PubMed] [Google Scholar]
  • 51.Finsterer J. Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia) J Neurol Sci. 2008;272:20–33. doi: 10.1016/j.jns.2008.05.011. [DOI] [PubMed] [Google Scholar]
  • 52.Maurer I, Zierz S, Moller H. Evidence for a mitochondria oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res. 2001;48:125–136. doi: 10.1016/S0920-9964(00)00075-X. [DOI] [PubMed] [Google Scholar]
  • 53.Jukic I, Titlic M, Tonkic A, Dodig G, Rogosic V. Psychosis and Wilson’s disease: a case report. Psychiatr Danub. 2006;18:105–107. [PubMed] [Google Scholar]
  • 54.Kumawat B, Sharma C, Tripathi G, Ralot T, Dixit S. Wilson’s disease presenting as isolated obsessive-compulsive disorder. Indian J Med Sci. 2007;61:607–610. doi: 10.4103/0019-5359.37047. [DOI] [PubMed] [Google Scholar]
  • 55.Srinivas K, Sinha S, Taly A, Prashanth L, Arunodaya G, Janardhana R, et al. Dominant psychiatric manifestations in Wilson’s disease: a diagnostic and therapeutic challenge! J Neurol Sci. 2008;266:104–108. doi: 10.1016/j.jns.2007.09.009. [DOI] [PubMed] [Google Scholar]
  • 56.Colsch B, Afonso C, Turpin J, Portoukalian J, Tabet J, Baumann N. Sulfogalactosylceramides in motor and psycho-cognitive adult metachromatic leukodystrophy: relations between clinical, biochemical analysis and molecular aspects. Biochim Biophys Acta. 2008;1780:434–440. doi: 10.1016/j.bbagen.2007.10.004. [DOI] [PubMed] [Google Scholar]
  • 57.Altintoprak A, Ersel M, Bayrakci A. An unusual suicide attempt: a case with psychosis during an acute porphyric attack. Eur J Emerg Med. 2009;16:106–108. doi: 10.1097/MEJ.0b013e32830abe2e. [DOI] [PubMed] [Google Scholar]
  • 58.Muntjewerff J, Hoogendoorn M, Kahn R, Sinke R, Den Heijer M, Kluijtmans L, et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. Am J Med Genet B Neuropsychiatr Genet. 2005;5:69–72. doi: 10.1002/ajmg.b.30179. [DOI] [PubMed] [Google Scholar]
  • 59.Sandu S, Jackowski-Dohrmann S, Ladner A, Haberhausen M, Bachman C. Niemann-Pick disease type C1 presenting with psychosis in a adolescent male. Eur Child Adolesc Psychiatry. 2009;18:583–585. doi: 10.1007/s00787-009-0010-2. [DOI] [PubMed] [Google Scholar]
  • 60.Walterfang M, Fietz M, Fahey M, Sullivan D, Leane P, Lubman D, Velakoulis D. The neuropsychiatry of Niemann-Pick type C in adulthood. J Neuropsychiatry Clin Neurosci. 2006;18:158–170. doi: 10.1176/jnp.2006.18.2.158. [DOI] [PubMed] [Google Scholar]
  • 61.Touati G, Valayannopoulos V, Mention K, de Longay P, Jouvet P, Depondt E, et al. Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. J Inherit Metab Dis. 2006;29:288–298. doi: 10.1007/s10545-006-0351-7. [DOI] [PubMed] [Google Scholar]
  • 62.Deutsch S, Rosse R, Yaseen M, Schulman H, Abraham S. Mitochondrial myopathy complicated by eating disorders: a case report highlighting the potential interaction of genetic, metabolic, and psychodynamic factors. CNS Spectr. 2007;12:289–292. doi: 10.1017/S1092852900021040. [DOI] [PubMed] [Google Scholar]
  • 63.Kim A, Francis J, Manos G. A case of MELAS presenting as anorexia nervosa. CNS Spectr. 2009;14:531–534. doi: 10.1017/S1092852900024019. [DOI] [PubMed] [Google Scholar]
  • 64.Feddersen B, LA DE Fontaine L, Sass J, Lutz J, Abicht A, Klopstock T, et al. Mitochondrial neurogastrointestinal encephalomyopathy mimicking anorexia nervosa. Am J Psychiatry. 2009;166:494–495. doi: 10.1176/appi.ajp.2008.08101525. [DOI] [PubMed] [Google Scholar]
  • 65.Gardeitchik T, Humphrey M, Nation J, Boneh A. Early clinical manifestations and eating patterns in patients with urea cycle disorders. J Pediatr. 2012;161:328–332. doi: 10.1016/j.jpeds.2012.02.006. [DOI] [PubMed] [Google Scholar]
  • 66.Schiff M, Benoist JF, Aïssaoui S, Boespflug-Tanguy O, Mouren MC, et al. Should metabolic disease be systematically screened in nonsyndromic autism spectrum disorders? PLoS ONE. 2011;6:e21932. doi: 10.1371/journal.pone.0021932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Enns G, O’Brien W, Kobayashi K, Shinzawa H, Pelligrino J. Postpartum, “psychosis” in mild argininosuccinate synthetase deficiency. Obstet Gynecol. 2005;105:1244–1246. doi: 10.1097/01.AOG.0000157769.90230.24. [DOI] [PubMed] [Google Scholar]
  • 68.Peterson D. Acute postpartum mental status change and coma caused by previously undiagnosed ornithine transcarbamylase deficiency. Obstet Gynecol. 2003;102:1212–1215. doi: 10.1016/s0029-7844(03)00165-0. [DOI] [PubMed] [Google Scholar]
  • 69.Fassier T, Guffon N, Acquaviva C, D’Amato T, Durand D, Domenech P. Misdiagnosed postpartum psychosis revealing a late-onset urea cycle disorder. Am J Psychiatry. 2011;168:576–580. doi: 10.1176/appi.ajp.2010.10071032. [DOI] [PubMed] [Google Scholar]
  • 70.Lichtenberg P, Navon R, Wertman E, Dasberg H, Lerer B. Post-partum psychosis in adult GM2 gangliosidosis. A case report. Br J Psychiatry. 1988;153:387–389. doi: 10.1192/bjp.153.3.387. [DOI] [PubMed] [Google Scholar]
  • 71.Michot JM, Sedel F, Giraudier S, Smiejan JM, Papo T. Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman. J Neurol Neurosurg Psychiatry. 2008;79:963–964. doi: 10.1136/jnnp.2008.143677. [DOI] [PubMed] [Google Scholar]

Articles from European Child & Adolescent Psychiatry are provided here courtesy of Springer

RESOURCES